GLPwatch
Papers (9189)
Page 75 of 154, ranked by citation count.
- Early liraglutide treatment improves β-cell function in patients with type 2 diabetes: a retrospective cohort study.
- Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months.
- The cardioprotective effect of human glucagon-like peptide-1 receptor agonist (semaglutide) on cisplatin-induced cardiotoxicity in rats: Targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways.
- Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data.
- Role of Vasopressin in the Regulation of Renal Sodium Excretion: Interaction with Glucagon-Like Peptide-1.
- Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.
- Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
- The effect of glucagon-like Peptide-1 receptor agonists on measures of suicidality: A systematic review.
- Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease.
- The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
- How 'miracle' weight-loss semaglutide promises to change medicine but can we afford the expense?
- Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
- Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus.
- Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.
- Evidence-Based Cardiovascular Risk Management in Diabetes.
- Dulaglutide-related bullous pemphigoid in a patient with type 2 diabetes: A case report.
- Acylation of exenatide by glycolic acid and its anti-diabetic activities in db/db mice.
- Enhanced Gut-to-Liver Oral Drug Delivery via Ligand-Modified Nanoparticles by Attenuating Protein Corona Adsorption.
- Optimization of pig models for translation of subcutaneous pharmacokinetics of therapeutic proteins: Liraglutide, insulin aspart and insulin detemir.
- The Effects of Exenatide Microsphere on Serum BGP and ALP Levels in ZDF Rats after Implantation.
- Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP.
- Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis.
- Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.
- Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3.
- A case report of allergy to exenatide.
- Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
- Exendin-4 inhibits HMGB1-induced inflammatory responses in HUVECs and in murine polymicrobial sepsis.
- Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.
- Insights into the central pathways involved in the emetic and behavioural responses to exendin-4 in the ferret.
- Liraglutide improved the reproductive function of obese mice by upregulating the testicular AC3/cAMP/PKA pathway.
- Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.
- The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
- Regional trends and disparities in newer GLP1 receptor agonist initiation among real-world adult patients eligible for obesity treatment.
- Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
- Liraglutide Accelerates Ischemia-Induced Angiogenesis in a Murine Diabetic Model.
- Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats.
- Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review.
- Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells.
- Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.
- Ectopic insulinoma diagnosed by 68Ga-Exendin-4 PET/CT: A case report and review of literature.
- Exendin-4 antagonizes the metabolic action of acylated ghrelinergic signaling in the hypothalamic paraventricular nucleus.
- Intentional overdose of liraglutide in a non-diabetic patient causing severe hypoglycemia.
- GLP-1 receptor signaling restores aquaporin 4 subcellular polarization in reactive astrocytes and promotes amyloid β clearance in a mouse model of Alzheimer's disease.
- Beta cell specific probing with fluorescent exendin-4 is progressively reduced in type 2 diabetic mouse models.
- 68Ga-NOTA-Exendin-4 PET/CT in Localization of an Occult Insulinoma and Appearance of Coexisting Esophageal Carcinoma.
- Dulaglutide and renal protection in type 2 diabetes.
- Exendin-4 induces a novel extended effect of ischemic tolerance via crosstalk with IGF-1R.
- Tirzepatide adds hepatoprotection to its armoury.
- Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).
- Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment.
- Liraglutide Improves the Kidney Function in a Murine Model of Chronic Kidney Disease.
- Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination.
- Liraglutide preconditioning attenuates myocardial ischemia/ reperfusion injury via homer1 activation.
- Key takeaways from the updated multidisciplinary European MASLD guidelines.
- Glucagon-Like Peptide-1 Inhibits the Progression of Abdominal Aortic Aneurysm in Mice: The Earlier, the Better.
- Design of Xenopus GLP-1-Based Long-Acting Dual GLP-1/Y<sub>2</sub> Receptor Agonists.
- Real-World Impact of GLP-1 Receptor Agonists on Endoscopic Patient Outcomes in an Ambulatory Setting: A Retrospective Study at a Large Tertiary Center.
- Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study.
- The role of incretin receptor agonists in the treatment of obesity.
- Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.